CWM LLC decreased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 13.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,301 shares of the company's stock after selling 12,773 shares during the quarter. CWM LLC owned approximately 0.29% of Establishment Labs worth $3,475,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Hood River Capital Management LLC bought a new stake in shares of Establishment Labs during the 2nd quarter valued at $43,000. Nkcfo LLC purchased a new position in shares of Establishment Labs in the second quarter valued at about $227,000. Concurrent Investment Advisors LLC purchased a new position in shares of Establishment Labs in the first quarter valued at about $263,000. SG Americas Securities LLC bought a new position in shares of Establishment Labs in the second quarter worth about $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Establishment Labs during the second quarter worth about $373,000. Hedge funds and other institutional investors own 72.91% of the company's stock.
Analyst Ratings Changes
A number of research firms recently commented on ESTA. Citigroup boosted their price target on Establishment Labs from $45.00 to $50.00 and gave the stock a "neutral" rating in a report on Tuesday, October 1st. BTIG Research upped their target price on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Monday. Stephens reiterated an "overweight" rating and issued a $68.00 price target on shares of Establishment Labs in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Establishment Labs from $61.00 to $50.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $58.83.
Read Our Latest Stock Analysis on ESTA
Establishment Labs Trading Up 3.6 %
Shares of NASDAQ:ESTA traded up $1.45 during trading on Monday, reaching $41.28. The company's stock had a trading volume of 314,767 shares, compared to its average volume of 378,879. The stock has a market capitalization of $1.14 billion, a PE ratio of -13.31 and a beta of 1.20. Establishment Labs Holdings Inc. has a 12 month low of $16.96 and a 12 month high of $60.12. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. The firm's 50 day simple moving average is $42.46 and its two-hundred day simple moving average is $46.82.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The company had revenue of $44.12 million during the quarter, compared to the consensus estimate of $43.10 million. During the same period in the previous year, the business earned ($0.65) earnings per share. Establishment Labs's revenue for the quarter was down 9.2% on a year-over-year basis. On average, research analysts predict that Establishment Labs Holdings Inc. will post -2.27 EPS for the current fiscal year.
About Establishment Labs
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
See Also
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
